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Abstract
Many hypotheses have been postulated to explain the intricate nature of the metastatic process, but none of them
completely accounted for the actual biological and clinical observations. Consequently, metastasis still remains an
open issue with only few metastasis-inducing proteins experimentally validated so far. Recently proposed novel
metastatic model, where serial and parallel metastatic processes are adequately integrated, might help to bridge
the current gap between experimental results and clinical observations. In addition, the identification, isolation and
molecular characterization of cancer stem cells, a population of the cells within the tumour mass able to
proliferate, self-renew and induce tumorigenesis, will shed new light on the complex molecular events mediating
metastasis, invasion and resistance to therapy. Understanding the molecular basis of these tumour characteristics
will usher in a new age of individualized cancer therapy. In this review article, we will provide a current overview
of molecular mechanisms underpinning metastasis, and discuss recent findings in this field obtained by global
molecular profiling strategies such as proteomics.
Introduction
Continuous technological advances in molecular biology
have paved the way for new discoveries in cancer
research. In particular, high-throughput profiling of
cancer tissue specimens and body fluids has been exten-
sively used in order to unveil specific molecular finger-
print of cancer [1-4]. Such strategy holds great promise
for diagnostics purposes, as it might distinguish between
different patients’ prognostic subgroups (good/poor),
which could provide the foundation for an individual
therapeutic approach towards each patient (tailored
therapy). However, in spite of these enormous efforts to
elucidate cellular and molecular mechanisms underlying
tumorigenesis, cancer still represents one of the dead-
liest scourges of the modern world.
Poor outcomes of current therapies, in particular poor
prognosis for patients in advanced stages of solid
tumours, have opened the possibility that tumour cells
include a population of cells responsible for the initia-
tion of tumour development, growth and its ability to
metastasize and reoccur. Because these cells share some
similarities with stem cells, they are referred to as
cancer stem cells (CSCs). CSC are undifferentiated cells
characterised by three major features: (1) potential to
differentiate into several or all types of cells that are
produced by the original tumour; (2) self - renewal abil-
ity; and (3) capacity to maintain the ‘stem cell pool’ and
the most mature tumour elements for unlimited time
periods [5]. CSC could originate from tissue-specific
stem cells and bone marrow stem cells, and somatic
cells that undergo trans-differentiation processes, or can
result from the fusion or horizontal gene-transfer pro-
cesses. The self-renewal and differentiation ability of
CSC gives rise to all tumour cell types, and thereby pro-
duces tumour heterogeneity. This relatively new per-
spective, the so-called “cancer stem cell” concept, casts
new light on the origins of cancer.
The relationship and differences between normal and
malignant stem cells remain unclear. In many
instances, normal stem cells, tumour stem cells and
metastatic stem cells share some common traits. Neo-
plastic stem cells were indeed shown to express similar
antigen pattern and to display similar functional prop-
erties in comparison with normal stem cells. Moreover,
it has been shown that for the maintenance and activa-
tion of both, normal stem cells and tumour stem cells,
the Wnt/beta-catenin signalling, Notch and PTEN
pathways are crucial [6]. Furthermore, growth of both,
normal and neoplastic stem cells, is often mediated by
t h es a m ec y t o k i n e s[ 7 ] .
Importantly, cancer/metastatic stem cells might be
discerned from embryonic stem cells by their propensity
to differentiate into the cell types within a particular
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tumour arises from tissue stem cells, and that cellular
components bearing stem-like properties govern tumour
formation. If cancer arises from rare population of cells
with stem-like characteristics, then it is plausible to pre-
sume that these stem cells differ from “normal” stem
cells in high rate of mutations. It is widely accepted that
stem cells undergo multiple mutations that are also
required for carcinogenesis, most probably due to their
long-lived nature [8]. Deregulation of self-renewal
mechanisms (e.g. Wnt/beta-catenin, Notch and Hedgehog
signalling pathways), which drive the stem cell expansion,
might be the early key event precipitating the formation of
CSCs in the particular tissue during the onset of carcino-
genesis. This hypothesis is further corroborated by the fact
that oncogenes may affect different stem cells and pro-
genitor cells resulting in phenotypic differences in
tumours, whereby it was shown that transgenes encoding
components of the Wnt/beta-catenin signalling pathway
preferentially induce mammary cancers from progenitor
cells [9]. Activation of oncogenes and inactivation of some
tumour-suppressor genes as the consequence of genomic
instability might drive transformation of normal stem cells
to CSCs. Several genes including AKT, TRAIL and
CXCL12 are recognised as candidate genes for cancer
stem cell progression and latent metastasis [10]. At last,
cancer/metastatic stem cells might exhibit higher expres-
sion levels of some genes (e.g. CXCR4, SDF1, VEGF), anti-
apoptotic proteins (Bcl-2 family inhibitors of apoptosis)
and transporter proteins (BCRP and P-glycoprotein), and
m i g h tr e m a i ni nt h eG 0 phase accounting for their resis-
tance to chemotherapy.
Methods that unequivocally identify CSC via specific
cell-surface protein markers might be diverse but have
many pitfalls. In vivo assays using NOD/SCID mice are
expensive and time consuming. Therefore, in vitro long-
term growth assays including sphere-formation assays,
serial colony-forming unit assays and label-retention
assays are often used in order to screen for stem cell
fractions or CSC-regulating compounds [6]. However,
the major drawbacks of these methods include: (1) lack
of tissue and tumour specificity; (2) inability to isolate
CSCs according to the degree of tumour differentiation;
(3) lack of species-specificity of CSC receptors and their
ligands and homing receptors in the tissue environment;
and (4) stem cell plasticity. At last, the general problem
for all in vitro studies is the selection pressure upon the
cultured cells, resulting in the selection of certain cell
population permissible to survive and proliferate under
specific conditions. Isolation of CSCs is also hampered
by the lack of specific CSC antigens or typical antigen
combinations not identified so far. These antigens might
include regular stem cells antigens such as cytokine
receptors, homing receptors (integrins, selectin-ligands,
chemokine receptors, cytoadhesion molecules and
ligands of matrix molecules such L1 or CD44) and var-
ious drug transporters [5,6].
Metastases show a great variety of clinical presenta-
tions/manifestations, mostly in correlation with the pri-
mary tumour localization [11]. For example, breast
cancer metastases can remain latent in the several years
follow-up after surgical removal of the primary lesion,
whereas metastases in patients with detected pancreatic
cancer and small-cell lung carcinoma are often wide-
s p r e a da tt h et i m eo fc a n c e rd iagnosis. Furthermore,
glioblastoma is locally progressive and invasive, but
rarely affecting secondary sites outside CNS. The effi-
cacy of common treatment regimens including radical
excision of the primary tumour followed by radiotherapy
and/or chemotherapy is limited and often fails to cure
the patient. Recent findings imply that some treatments
(e.g. irradiation at certain regimen, Taxol etc.) do not
target the CSCs responsible for tumour development.
Moreover, such treatment might have a completely
opposite effect, e.g. to produce more cancer cells capable
of metastasizing [12-14]. Indeed, it is widely accepted
that CSC have a dormant nature and abundantly express
drug transporters [15], which could provide a plausible
explanation for resistance to standard chemotherapy
known to target dividing cells. Consequently, 90% of
deaths of the patients with solid tumors are attributed
to local invasion and distant metastases [11].
Metastatic model - “serial” or “parallel"?
The molecular mechanisms of metastasizing are still
covered by the veil of mystery. The application of geno-
mic profiling methods (DNA microarray) combined
with either animal models of metastasis or laser capture
microdissection (LCM) providing in vivo insight into
molecular processes underlying metastatic progression
have fostered the research of its complex molecular nat-
ure. So far, the so-called “serial” model of clonal pro-
gression has been generally accepted explaining that
metastatic cells originate from the primary tumour and
represent the end stage of tumorigenesis. Although the
metastatic genotype contains additional genetic muta-
tions, its spectrum of aberrations is thought to be simi-
lar to that found in the primary lesions [16], as
augmented by the findings of kariotypic and genomic
analyses of the breast, bladder, colon and kidney malig-
nancies [17-24]. Surprisingly, some of these studies indi-
cate the existence of metastases with lack of (without)
genetic similarity to the primary tumour [18,20,25]. Bis-
sig et al. [18] showed that 30% of renal cell metastases
have almost completely different genotype in compari-
son with the primary lesion cells isolated from the same
patient. Furthermore, a genomic study of metastatic
breast cancer [20] presented a significant amount of
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resemblance to the tumour of primary origin. Finally,
the analysis of metastatic lesions at several sites in the
same individuals showed a substantial evolutionary
divergence between metastatic lesions and primary
tumour, as well as between the metastases themselves.
Schmidt-Kittler et al. [25] reported unexpected results
providing novel insight into metastatic progression. In
this study, patients were divided into two groups accord-
ing to clinical presence or absence of metastatic dissemi-
nation (M0- no metastatic disease; M1-metastasis
positive). The results of comprehensive genomic analyses
of the primary tumour specimens and single cytokeratin-
positive (CK+) epithelial cells from the bone marrow of
the corresponding patients were as follows: (1) the CK+
cells from M0 patients showed about half as many geno-
mic aberrations as those from M1 patients; and (2) most
of the CK+ cells from M0 patients showed little similarity
to the primary tumour. To sum up, cells from M0
patients showed whole chromosome copy number aber-
rations, while cells from M1 patients showed sub-chro-
mosomal changes typical for aberrations that appear
during telomere crisis. The authors suggest that eventual
appearance of clinically detectable metastases in M0
patients could be a consequence of early disseminated
cells, which evolve and pass through crisis independently
of the primary tumour. Due to slow evolution of these
disseminated cells, as well as their persistence during a
long period, the results of this study offer an explanation
for the appearance of clinically evident metastatic disease
years after treatment of the primary tumour that was pre-
sumed to be successful and curative [16]. A comparison
of genetic fingerprints among disseminated cells from
M0 patients with those from metastatic cells that will
arise during the follow-up after primary tumour treat-
ment is of utmost importance for the “parallel” theory.
Similarly, Hüsemann et al. [26] showed that cancer cells
can spread systematically from earliest epithelial altera-
tions in HER-2 and PyMT transgenic mice and from duc-
tal carcinoma in situ (DCIS) in women, thus providing
additional evidence that supports the novel outlook on
the onset of metastatic spreading and its parallel progres-
sion (evolution) during tumorigenesis. This “parallel”
concept is, nevertheless, based on several pioneering stu-
dies [27,28], the first one being the experimental docu-
mentation in human leukemias [29] that shaped the
concept of ‘cancer stem cells’.
Since initiation of metastasis process is inherent to
CSCs, the metastatic progression should be thus studied
as an independent and “parallel” process in tumorigen-
esis governed by the so-called EMT (epithelial to
mesenchymal transition) that occurs among tumour
cells. The majority of tumours are epithelial but exert
mesenchymal characteristics. During tumour invasion,
tumour cells move from the primary tumour site and,
similarly to the cells in epithelia during normal embryo-
nic development, lose epithelial characteristics and cell-
to-cell contacts, and acquire the mesenchymal gene
expression [30]. Such cells are then capable of invading
distant sites (Figure 1). The changes occurring in the
cell-to-cell adhesions forces as well as in the cytoskeletal
cortex association to plasma membranes are therefore
central to the invasion, migration and intravasation of
tumour cells. According to this, epithelial cells might be
somehow “induced” to become metastatic by several fac-
tors such as chemokine CCL5 [31] and transcription
factors FOXC2, Twist, Snug, Snail and ZEB1 [13,32]
that were shown to drive the EMT programme. The
EMT process might account for some similarities found
between embryonic stem cells and the stem cell-like
traits in neoplastic cells. One must, however, always
have in mind that not every EMT-inducing factor dis-
covered will necessarily elicit a stem-like profile.
As recently nicely reviewed by Hurt and Farrar [33],
the question remains whether the existing CSCs or
rather those cells that escaped the primary tumour and
acquired the stem cell-like phenotype through the EMT
process, induce distant metastases. Further research
based on the use of powerful imaging methods and in
line with the in vivo study performed by Condeelis et al.
[34] showing the convincing images of individual cells
delaminated from primary tumours, will be needed to
Figure 1 The epithelial-mesenchymal transition (EMT) occurs at
the primary tumour site where epithelial cells lose tight
junctions and apico-basal polarity. The remodelling of the
cytoskeleton occurs as well. The invasion process through the
extracellular matrix (ECM) is frequently led by so called tumour-
associated fibroblasts. EMT can induce stem-cell-like properties in
cells. The question still remains whether the existing cancer stem
cells or rather those cells that escaped the primary tumour and
acquired the stem cell like phenotype through the EMT process
induce distant metastasis.
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peutic modalities will be required to target indepen-
dently evolved metastatic cells after early separation
from the primary tumour, which will lay the ground-
work for further improvement of therapeutic efficacy.
Organ tropism and metastatic gene signature
The molecular basis of organ tropism, one of the main
features of metastasis, is still obscure. It has been well
documented that different types of cancer produce
metastases at preferred secondary sites, depending on
the tissue susceptibility to specific metastatic cells. Bone
metastasis is often associated with breast, prostate or
lung cancer, while it is rarely detectable in patients with
diagnosed colorectal cancer [35]. This preferential devel-
opment of macrometastases at distant secondary organs
can be partially explained by the pattern of blood flow.
Nevertheless, molecular interactions between metastatic
cells (seeds) and stromal microenvironment (soil) have
been proven to mediate efficiency of metastatic forma-
tion and its tissue specificity [35]. When it comes to the
role of tumour microenvironment in tumour dissemina-
tion, early changes observed in tissue before evidence of
carcinogenesis might be critical for tissue-specific metas-
tasis. For example, the inflammatory response, matrix
remodelling and increase in reactive oxygen species
often precede tumour metastasis. Accordingly, it has
been recently shown that alteration in the expression of
metalloproteinase 9 precedes metastasis in lung [36].
The same studies also showed that arrival of bone mar-
row-derived hematopoietic progenitors expressing vas-
cular endothelial growth factor receptor 1 in distant
sites, which fosters inflammation and sustains tumour
growth, represents some of the early changes present in
the local microenvironment and necessary for metas-
tases to occur [37].
Genetic and phenotypic characteristics of tumours
have also been studied as factors linked to organ-specific
metastases [38-40]. Kakiuchi et al. [39] reported differ-
ential gene expression profiles for lung, liver, kidney and
bone metastases. Another research group [38] investi-
gated metastatic potential of human breast cancer using
MDA-MB-231 cell line, originally derived from the
pleural effusion of a patient with metastatic dissemina-
tion. After injection into immunodeficient mice, metas-
tases were detected in bone and adrenal medulla.
Subsequently, human cells were re-isolated from the
osteolytic bone metastases, and sublines with high meta-
static potential were observed. Microarray profiling of
these sublines revealed that the gene expression signa-
tures directly correlated with metastases. The authors
were able to distinguish cells with tendency to dissemi-
nate to bone or adrenal medulla, as the two groups
showed differential gene expression patterns. A set of
CXCR4, IL-11, CTGF and MMP1 genes, if co-expressed
with the gene encoding osteopontin, correlated with
bone-specific metastatic potential. Each of these genes,
when expressed alone, failed to cause high metastatic
potential. Thus, the set of genes found in the bone
metastasis signature seems to be a causative factor in
metastasizing to the bone. Furthermore, Minn et al. [40]
identified a set of 54 genes with differential expression
in lung-tropic breast cancer sublines in comparison with
bone-tropic lines. The identified set of 54 genes in lung-
tropic gene signature is probably not the only gene set
responsible for metastasizing to the lungs, because a
small amount of investigated primary tumours expressed
this specific signature. Therefore, it is logical to presume
that other lung-tropic metastatic signatures are yet to be
discovered. Recent gene expression profiling studies
revealed an association between Src pathway activity and
late-onset bone metastasis in breast cancer, which is
independent of hormone receptor status and breast
cancer subtype [10]. Src activity was shown to be
required for CXCL12 activation of the AKT cell survival
pathway and for the resistance of metastatic breast
cancer cells to the pro-apoptotic effects of TRAIL, both
of which are predominantly expressed in the bone metas-
tasis microenvironment. In view of these findings, target-
ing Src signalling pathway might provide a novel strategy
to suppress the survival of disseminated cancer cells.
Although it is widely accepted that some primary
tumours are predestined to metastasize to specific organ,
it is still unclear when and how exactly they acquire
organ-tropic gene signatures [41]. Furthermore, the com-
plex multistep nature of metastasis process suggests that
vast arrays of genes are responsible for its regulation.
Addressing the question of metastatic prediction, recent
analyses of human cancer specimens using DNA micro-
array technology suggest that patients can be divided into
prognostic subgroups, based on the “good” or “poor”
gene expression signature of the primary tumour, which
predicts the risk of metastasis appearance after tumour
resection, particularly evaluated in breast cancer
[4,42,43]. Traditionally, in clinical practice, the potential
of its metastatic recurrence is in correlation with primary
tumour size and histological grade. In a recent study,
Ramaswamy et al. [44] compared gene signatures of pri-
mary adenocarcinomas and metastases from a similar set
of adenocarcinomas. Their analysis revelaed a “metastatic
gene signature” common to many different tumour types.
When detected in some primary tumours, this signature
indicated its pre-existed tendency to metastasize and,
therefore, had a significant prognostic value. Neverthe-
less, evaluation of this metastatic signature once the pri-
mary tumour is diagnosed distinguishes tumours with
local growing potential from those preconfigured to dis-
seminate to distant sites [44,45]. However, it remains
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factors in metastatic spreading or indirect indicators of
metastatic potential [46].
Besides screening for genes linked to metastasis organ
tropism, the stem cell theory might provide an additional
explanation for this phenomenon. In fact, it has been
well documented that CSCs express a G-protein-coupled
seven-span transmembrane receptor CXCR4 on their
surface similarly to normal stem cells for different
organs/tissues [47]. Facts about the role of chemokines,
small pro-inflammatory chemoattractant cytokines that
bind to G-protein transmembrane receptors of target
cells, in mediating cell trafficking might additionally illu-
minate how metastases are attracted to specific organs.
For example, a stromal-derived chemokine SDF-1 exclu-
sively binds to CXCR4 and is highly expressed in lymph
n o d e s ,l u n g ,l i v e ro rb o n e s .T h e r e f o r e ,m e t a s t a s i so f
CXCR4+ tumour cells might be driven specifically to
these organs through the SDF1-CXCR4 axis [47]. This
assumption is augmented by the findings revealing that
several CXCR4+ cancers such as breast, ovarian and
prostate cancer metastasize to bones from bloodstream
in a SDF-1 dependent fashion [47,48]. However, possible
therapeutic strategies based on modulation of the
SDF1-CXCR4 axis or other chemokines involved in stem
cell trafficking should be carefully considered, as this sig-
nalling pathway is normally involved in the trafficking of
stem cells.
Molecular mechanisms of metastasizing
Metastasis is apparently central in terms of clinical man-
agement of cancer, as the preponderance of patients’
deaths are associated with disseminated disease rather
than the primary tumour. Moreover, patients with small
primary tumours and node negative status (T1N0) at sur-
gery often (15% to 25%) develop distant metastases [49].
As summarized in this paper, recent literature data sup-
port the concept of metastasis as a second disease imposed
on the primary tumour, where the outcome of metastasis
is determined by the interplay between the specific subpo-
pulation of metastatic cells and host homeostatic factors
in specific organ microenvironment including vasculature.
However, over the past decades, the so-called progression
model has been widely accepted among clinicians and
researchers. This model depicted metastasis as a result of
several consecutive mutational events occurring either in
subpopulations of the primary tumour or disseminated
cells, and yielding a small fraction of cells that acquire full
metastatic potential. Recently, several microarray studies
have prompted reexamination of the progression model,
as they enable identification of gene signatures that can
distinguish metastatic from non-metastatic tumours, and
postulate that metastatic propensity is established early in
oncogenesis [44,45]. Accordingly, metastatic genes can be
classified into several groups: metastasis initiation genes,
metastasis progression genes and metastasis-virulence
genes [11]. Metastasis initiation genes provide an advan-
tage in a primary tumour and enable tumour cells to enter
the blood-flow. Most genes mediating tumour cell moti-
lity, invasion or angiogenesis belong to this group. This
class includes genes involved in EMT and caspase 8,
whereby loss of caspase 8 function protects tumour cells
from programmed death due to release of integrin-regu-
lated anchoring at the invasive front [30,50,51]. The sec-
ond class of metastatic genes, specified as the metastasis
progression genes fulfil some rate-limiting functions in
primary tumour growth and other specific functions in
metastatic colonization. These genes can be found within
organ-tropic gene signatures, thus causing specific advan-
tage restricted to particular distant organ. Nevertheless,
while metastasis-virulence genes participate in metastatic
colonization due to selective advantage in secondary sites,
they do not affect the primary tumour development [11].
Therefore, these genes promote aggressiveness of meta-
static tumour cells at the level of colonized distant organs.
Recent study dealing with organ-specific metastases in
breast cancer reported on the lung-tropic metastatic gene
set comprising 54 genes, among which only 18 were
expressed in primary tumours. These results provide an
evidence for the existence of metastasis progression genes
and metastasis virulence genes [40,52]. Both groups of
genes enable circulating tumour cells to colonize the
lungs. The 18 genes expressed in the primary tumour
induce primary tumorigenesis, leading to the larger
tumour size at the time of diagnosis. Due to vascular-
remodelling programme, three out of those 18 genes
(EREG, COX2 and MMP1) facilitate tumour angiogenesis
and intravasation in mammary tumours. In addition, they
act as a mediator in tumour cells extravasation from the
lung capillaries. Accordingly, the EREG, COX2 and
MMP1 genes are classified as metastasis progression
genes.
Introduction of improved molecular research methods
has opened new chapter in metastasis research by specifi-
cally disclosing some of the underlying molecular events
in metastatic progression. Molecules which play an impor-
tant role in processes involving cell-cell adhesion, migra-
tion, proteolysis, chemotaxis, angiogenesis and signal
transduction have been investigated with aim to decipher
their activity in evolution of metastasis [35]. Five candidate
metastasis genes, namely CXCR4, IL-11, CTGF, MMP1
and osteopontin from the bone metastasis signature
reported by Kang et al [38] encode secreted cytokines or
cell surface receptors, which is consistent with traditionally
accepted idea that metastasis formation is a consequence
of pathological interactions between tumour cells and
stromal microenvironment. The evidence for this widely
accepted theory is provided by Hu et al. [53], who used
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breast tumours. The authors found that myoepithelial cells
and fibroblasts mediate the transition from DCIS to inva-
sive carcinoma. In the absence of normal myoepithelial
cells, co-injection of fibroblasts promoted progression of
in situ to invasive carcinoma. On the contrary, co-injection
of normal myoepithelial cells effectively suppressed
tumour weight, despite presence of progression-promoting
fibroblasts. The obtained results were not the upshot of
permanent genetic aberrations in the epithelial tumour
cells. Furthermore, TGF-b and Hedgehog signalling were
recognized to have a critical role in breast tumour pro-
gression, while decreasing TGF-b and Hedgehog pathway
activity via TGFBR2/SMAD4 downregulation and Gli2
expression resulted in the loss of myoepithelial cells and
accelerated invasion.
Even if a wealth of evidence supports this model,
some paradoxes still remain. First, in many tissues
where tumours arise, normal mature cells have a short
lifespan. Consequently, the chances to accumulate muta-
tions required for tumour development are rather lim-
ited. Secondly, patients diagnosed with disseminated
disease with unknown primary cancer metastatic disease
have no clinically detectable primary tumour or only a
small, well differentiated lesion that is found at autopsy
[54]. Furthermore, although variant clones with high
metastatic capacity can be identified in populations, it is
frequently observed that these variants revert to a low-
metastatic capacity after several generations [55,56]. The
so-called transient metastatic compartment model pro-
posed by Weiss et al [57] suggests that all viable cells in
a tumour might acquire metastatic capacity as explained
by the progression model, but due to their position in
the primary tumour and random epigenetic events, only
a small fraction of these cells are competent to metasta-
size at a given moment in time. Thus, not all cells
within a tumour preserve the capacity to disseminate to
secondary sites as a result of accidental, or microenviro-
mentally induced epigenetic events or inadequate access
to vasculature. However, this model fails to explain the
clonal nature of metastases. If every cell had a meta-
static ability modulated only by momentary epigenetic
events, then it would be less likely that significant pro-
portions of secondary tumours would appear to be of
clonal origin.
Another intriguing theory, the so-called cell fusion
theory, explains that the acquisition of metastatic phe-
notype occurs when a healthy migratory leukocyte fuses
with a primary tumour cell. Such a ‘hybrid’ has the
innate blood cell ability to migrate through the body
while still keeping the uncontrolled cell processes as
occurring in the tumour cells [58,59]. Interestingly, the
fusion of genetic and cytoplasmic material between cells
of different origins is an important physiological process
during development. Generally, cell fusion and horizon-
tal gene-transfer events could be important in the devel-
opment of the CSCs [60]. Substantiating these theses,
the inv i t r ofusion of cells was proved to produce sub-
clones with varying metastatic potentials [61,62], and
over 30 reports confirming cancer cell fusion in animal
tumour models have been published so far [63,64]. In
addition, a number of factors such as cellular or viral
fusion proteins or environmental factors may provoke
cell fusion of tumour and normal cells. Such fused cells
will probably die or become quiescent. Nevertheless,
there is a small fraction that will maintain the ability to
proliferate and generate malignant cells. It has been
shown that endothelial cells in solid tumours might be
aneuploid with multiple chromosomes and multiple cen-
trosomes, implying the possibility of cell fusion between
tumour cells and endothelial cells [65]. This theory has
yet to be confirmed in humans as well.
Technological advances in metastasis research:
proteomics
Global transcriptome profiling of cancer has undoubtedly
improved our knowledge of tumour biology, and has led
to the discovery of novel therapeutic and imaging targets,
as well as potential prognostic and predictive biomarkers
for diverse cancer types. However, transcriptomics can
predict neither the expression level nor the functional
status determined by folding, post-translational modifica-
tions, cellular localization and molecular interactions of
the key signalling molecules in complex protein networks
integral to cancer pathogenesis. For example, how exactly
and when the EMT process and other pro-survival sig-
nalling cascades in cancer cells are triggered, still remains
to be elucidated. Cancer may be genetically based, but on
the functional level, it is a proteomic disease [66],
because tumour progression, invasion, and metastasis
depend on the functional activity of many proteins, such
as growth factors and proteases.- Consequently, molecu-
lar oncologists have been turning more to proteomics
technologies (Table 1) as to identify novel protein bio-
markers specifically associated with metastatic transition,
and to decipher signal transduction pathways that propel
the cells down the road towards metastasis. Such techno-
logical approach should provide an early detection and
prediction of metastatic processes, and reveal novel tar-
gets for drug development and therapeutic intervention.
There is now an enormous wealth of literature data on
employing proteomics in metastasis research covering
practically all tumour types, and discovered biomarkers
might be correlated with the metastatic process and/or
cancer stem cell phenotype. Some recent examples will
be briefly discussed below.
2-DE followed by MALDI-TOF MS analysis represents
the workhorse of the vast majority of published
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Proteomics
method
Abbreviation Basic principle Biological Application Advantages Limitations
Two-dimensional
gel electrophoresis
2-DE Proteins are first resolved
by their isoelectric points,
and then by molecular
weights
Separation of proteins in
complex biological
samples
High resolution Very
sensitive
Direct detection of
post-translational
modifications
Limited automation
Problematic gel-to-gel
reproducibility
Problematic recovery of
hydrophobic and large
molecular weight proteins
Limited dynamic range of
detection
Two-dimensional
difference gel
electrophoresis
2D-DIGE Samples are labelled with
two spectrally distinct
fluorescent cyanine dyes,
and run on the same 2-DE
gel; the two gel images
corresponding to each dye
scan are then overlaid, and
the intensities of paired
spots are compared across
the gel images
Quantification of the
differences in protein
expression between
different samples
High sensitivity
Accurate quantitation
Good reproducibility
Expensive fluorophores,
equipment and software
Matrix assisted laser
desorption
ionisation time-of-
flight mass
spectrometry
MALDI-TOF
MS
Tryptic digests of sample
proteins are co-crystallized
with matrix, and spotted
onto MALDI plate;
ionization occurs by pulsed
laser radiation primarily
absorbed by the matrix,
causing desorption and
ionization of the analyte;
the resulting peptide ions
are directed into TOF mass
analyzer, where peptide
masses are measured by
determining the time
required for the ions to
traverse the length of the
flight tube and reach
detector
Protein identification
Amino-acid sequencing
Determination of the type
and position of post-
translational modifications
Produces less raw data
than other MS
techniques
Data are relatively easy
to interpret since most
peptides carry only one
charge and are present
as a single peak in a
spectrum
Requires previous
separation of protein
mixture
Hampered identification of
small acidic and integral
membrane proteins
Multidimensional
protein
identification
technology
MudPIT Mixture of tryptic peptides
is resolved by the
microcapillary column
packed with reversed-
phase resin followed by
strong cation exchange
resin; peptides are eluted
directly from the column
into the mass spectrometer
to be rapidly analyzed
Large-scale protein analysis
of complex biological
mixtures
Identification of protein
complexes
Determination of post-
translational modifications
Quantitative analysis of
protein expression
Detects proteins of
wide range of pI,
abundance and sub-
cellular distribution
Employed directly on
crude samples
Easily automated High
resolving power
High sensitivity
Time-consuming Requires
experienced personnel
Does not detect protein
activity nor interactions
Limited throughput
Generates the vast stream
of raw data
Surface enhanced
laser desorption
and ionization time-
of-flight mass
spectrometry
(ProteinChip
Technology)
SELDI-TOF
MS
Protein solutions are
applied to the spots of
ProteinChip Arrays that
contain either chemically
(anionic, cationic,
hydrophobic, hydrophilic,
or metal ion) or
biochemically (immobilized
antibody, receptor, DNA,
enzyme, etc.) active surface
retaining proteins
according to their specific
physicochemical properties;
after adding matrix solution
to bound proteins, the
latter are ionized with
nitrogen laser and their
molecular masses
measured by TOF mass
analyzer. As a result, unique
protein abundance profiles
of species bound to the
chip surface are obtained.
Biomarker discovery
Characterization of protein-
protein and protein-DNA
interactions and post-
translational modifications
(glycosylation and
phosphorylation)
Suitable for crude
biological samples
(body fluids, cells)
High-throughput
capability
High sensitivity
Detects proteins with
molecular weights
lower than 6-kDa
High precision and
reproducibility
Additional MS analysis
needed for determining
the identity of differentially
expressed protein species
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approach has proved effective in measuring protein
expression patterns within cells, tissues and bodily fluids
uncovering many novel metastasis-related proteins, such
as chloride intracellular channel 1 (CLIC1). CLIC1 was
specifically correlated with metastasis of gallbladder car-
cinoma, the most frequent form of bile duct cancer, as
its expression was significantly up-regulated in the
highly metastatic gallbladder cancer GBC-SD18H cell
line when compared to the poorly metastatic GBC-
SD18L cell line [67]. In addition, the overexpression of
CLIC1 promoted cell motility and invasion of GBC-
SD18L cells, while RNA interference of CLIC1 remark-
ably decreased cell motility and invasive potency of
GBC-SD18H cell line. Similarly, proteomics profiling of
tumor tissues from gastric cancer revealed CLIC1 to be
significantly up-regulated in 67.9% of the patients [68].
This study revealed significant correlation between ele-
vated expression of CLIC1 and lymph node metastasis,
lymphatic invasion, perineural invasion, advanced patho-
logical stage and poor survival in gastric cancer, which
highlights the role of CLIC1 in tumor invasion and
metastasis in gastric cancer.
S100A11 protein is a calcium-binding protein implicated
in a variety of biological functions such as proliferation
and differentiation, whose relation with tumor progression
and invasion was substantiated by recent proteomics stu-
dies. Tian et al. [69] carried out comparative 2-DE/
MALDI-TOF MS analysis of non-metastatic and highly
metastatic non-small cell lung cancer (NSCLC) cell lines
and found S100A11 to be specifically up-regulated in the
metastatic cell line. Immunohistochemical staining of 65
Table 1 Overview of the most common proteomics technologies in the research of tumour invasion and metastasis
(Continued)
Isotope-coded
affinity tags
ICAT Two different protein
samples are labelled at
cysteines with the
isotopically light and heavy
ICAT reagents, combined
and digested with trypsin;
ICAT-labeled peptides are
isolated by avidin affinity
chromatography and
analyzed by HPLC coupled
to a tandem mass
spectrometer; the ratio of
ion intensities from co-
eluting ICAT-labeled pairs
permits the quantification,
while a subsequent
MS/MS scan provides the
protein identification
Sequence identification
and quantification of
proteins in complex
mixtures
Analysis of protein changes
in specific subcellular
fractions
Selects only cysteine-
containing peptides
and thus effectively
reduces the complexity
of the peptide mixtures
Incomplete proteome
coverage (10-20% of the
whole cell proteome)
Laser-capture
microdisscetion
LCM A stained tissue slide is
placed under a microscope,
and a specific
thermoplastic polymer film
is placed over the tissue;
the cells of interest are
shot by an infrared laser
pulse, which melts and
fuses the film around the
targeted cells; the cells
embedded in the polymer
are lifted away from the
remaining tissue
Isolation of pure cell
populations from
heterogeneous tissue
sections prior to proteomic
analyses focused on the
investigation of novel
biomarkers and drug
targets
High-throughput
Reduces sample
heterogeneity
Increases the specificity
of signals obtained in
downstream protein
analysis
Requires competency in
identifying the cells of
interest
Limited timeframe for
microdissecting fresh
frozen tissue.
Reverse-phase
protein microarrays
RPMA Cell lysates are arrayed on
nitrocellulose-coated glass
slides binding denatured
proteins; the slide is
probed with a single
antibody specific for an
antigen of interest; upon
signal development and
imaging, the relative
proportion of the analyte
protein molecules can be
compared between test
samples on the array
Functional mapping of
known cell-signalling
networks or pathways
Characterization of protein-
protein, protein-DNA, and/
or protein-RNA interactions
High-throughput
Requires low sample
volume
Extremely sensitive
analyte detection
Good reproducibility,
sensitivity, and
robustness
The lack of availability of
high-quality, specific
antibodies
Hampered analysis of low-
abundance post-
translational events
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Page 8 of 14primary NSCLC tissues and 10 matched local positive
lymph node specimens confirmed that the over-expression
of S100A11 in NSCLC tissues was significantly associated
with higher tumor-node-metastasis stage and positive
lymph node status, implying regulatory role of this protein
in promoting invasion and metastasis of NSCLC [69].
Using the same proteomics strategy, S100A11 was also
reported to be up-regulated in metastatic hepatocellular
carcinoma (HCC) tissues [70], and to rise in the expres-
sion level with the progression of colorectal cancer [71]. In
view of these studies, S100A11 protein might be consid-
ered as useful candidate molecule for early diagnosis and
intervention of NSCLC, HCC and colorectal metastases.
The development of fluorescent dye labels allowing
the comparison of two different samples on a single gel
referred to as 2-D fluorescence difference gel electro-
phoresis (2-D DIGE) has improved reproducibility, more
accurate quantitation and spot statistics between gels in
comparison with conventional 2-DE. This method was
successfully applied to screening potential biomarkers
for early detection of prostate cancer and lung squa-
mous carcinoma metastases. Pang et al. [72] analyzed
protein samples from localized and lymph node meta-
static prostate cancer (LNM PCa) as well as benign pro-
static hyperplasia tissues, and found increased
expression of e-FABP5, MCCC2, PPA2, Ezrin and SLP2
along with reduced expression of SM22 in LNM PCa
tissues. Importantly, e-FABP5 levels were significantly
increased in the sera of patients with LNM PCa. These
findings were in line with the previous studies revealing
an over-expression of e-FABP5 protein in PCa tissues
[73]. Overexpression of e-FABP5 was shown to induce
metastasis by up-regulating VEGF, which plays a crucial
role in the metastatic cascade [74]. Therefore, increased
e-FABP expression is a possible target to inhibit the
malignant progression of prostate cancer cells. Using the
same technique, Yao et al. [75] compared the protein
profiles between laser capture-microdissected (LCM)
lung squamous carcinoma (LSC) cells with and without
lymph node metastasis (LNM), and found rise in the
expression level of HSP27, Annexin A2, and CK19,
whereas 14-3-3 s had reduced expression in LNM LSC.
Additional immunohistochemical analyses confirmed
that these proteins are indeed correlated with several
clinicopathological variables and prognosis of LSC.
The increasing use of high-throughput platforms for
the analysis of protein expression levels driven by tech-
nological improvements in mass spectrometry and
array-based technologies has pushed the boundaries of
clinical oncoproteomics. Serum protein pattern profiling
by ProteinChip Technology (SELDI-TOF MS) has
emerged as novel approach to discover protein signa-
tures capable of discriminating patients with primary
cancer from those with metastasis, as demonstrated by
several recent studies on laryngeal squamous cell carci-
noma [76], colorectal [77], ovarian [78], lung [79], pros-
tate [80], breast [81] and gastric cancer [82].
Collectively, these studies clearly showed diagnostic and
prognostic value of ProteinChip technology. In addition,
Goncalves et al. [83] used this proteomics approach on
a high-risk early breast cancer population receiving stan-
dard adjuvant chemotherapy, and managed to identify a
post-operative serum proteomic profile that might pre-
dict metastatic relapse. Currently, there are no satisfac-
tory screening and early diagnostic strategies for
metastatic cancer. Due to its quantification capability
and reproducibility, SELDI-TOF MS represents a serious
candidate tool for rapid and accurate high-throughput
screening of cancer patients.
Major breakthrough in metastasis research represents
the combination of LCM and protein microarray tech-
nologies, which has been applied to the analysis of
human metastatic breast and ovarian cancer tissue sam-
ples in phase II clinical trials at the National Institutes
of Health National Cancer Institute [84]. Similarly, Shee-
han et al. [85] utilized reverse phase protein microarray
(RPMA) technology to profile a matched cohort of pri-
mary and metastatic ovarian carcinomas using phos-
phorylation-specific antibodies. Strikingly, the metastatic
signatures were clearly very different from the primary
tumor taken at the same time at surgery, and these fin-
gerprints appeared to be virtually patient-specific, which
underscores the critical need for patient-tailored therapy
designed to specifically target the disseminated cells.
The same study revealed several phosphorylated pro-
teins that were differently expressed between primary
and metastatic tissues, including the phosphorylated
forms of c-Kit, Ask, myristoylated alanine-rich C kinase
substrate, IBa, and Ras-GRF [85]. Importantly, metas-
tasis correlated with activation of c-Kit, which was pre-
viously demonstrated to pertain to advanced stage and
chemotherapy resistance in serous ovarian carcinomas.
RPMA technology has also proved beneficial in inves-
tigating the cellular events that accompany metastatic
progression, as exemplified by Paweletz et al [86] who
used RPMAs to compare LCM-specimens of histologi-
cally normal prostate epithelium, prostate intraepithelial
neoplasia, and invasive prostate cancer. Amplification of
antibody-antigen complexes on the microarrays revealed
a statistically significant increase in phosphorylation of
Akt and a decrease in phosphorylation of Erk in prema-
lignant and invasive prostate cancer. The authors draw a
conclusion that these shifts in protein abundance indi-
cated activation of pro-survival signaling pathways with
cancer invasion. The same study also demonstrated that
downstream components of the apoptotic cascade,
namely cleaved and noncleaved caspase-7 and PARP
were also shifted towards prosurvival function during
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authors proposed a hypothetical model of prostate can-
cer progression according to which activation of Akt
suppresses apoptosis, probably via inactivation of its
substrate GSK3-b, which might cause an imbalance
between cell proliferation and death leading to the accu-
mulation of cells within prostate gland [86]. Simulta-
neously, transient ERK activation and turning on pro-
survival pathways might be associated with cellular
migration responsible for invasion. Akt seems to play a
central role in prostate cancer metastasis, as its activa-
tion could foster cell motility and survival during stro-
mal invasion.
Despite rapid development of proteomics technologies,
cancer stem cell proteomics is still in its infancy. This
c o u l db ea s c r i b e dt ot h ee x t r emely low availability of
putative CSCs, as these cells represent only a small frac-
tion of the overall cancer cell population. In addition, the
methods for isolating a large enough sample of pure
CSCs have not been developed yet [87]. However, recent
proteomics studies on leukemic [88,89] and pancreatic
cancer stem cells [90] are bright examples on how to suc-
cessfully overcome the issue of sample limitations in CSC
research. Tibes at al. [88] demonstrated that RPMAs
could be reliable, reproducible high-throughput approach
for analyzing protein expression and phosphorylation sta-
tus in primary acute myelogenous leukemia cells, cell
lines and stem cells. Importantly, this group of authors
found that leukemic stem cells had apparently different
protein signature compared with normal stem cells, and
observed different levels of protein expression when nor-
mal and leukemic CD34+/CD38+ and CD34+/CD38- cells
were compared, or when leukemic and normal stem cells
were compared. Novel perspective on human leukemo-
genesis was provided by Ota et al. [89], who utilized
2-DE/MS for protein profiling of isolated AC133
+ leuke-
mic blasts from 13 individuals with acute leukemia or
related disorders. They detected 10 differentially expressed
proteins including NuMA, heat shock proteins, and redox
regulators. An over-expression of HSP70 family proteins
in leukemic blasts was proposed to be directly associated
with leukemogenesis, or to the development of drug resis-
tance. Importantly, the finding that the abundance of the
nuclear mitotic apparatus protein (NuMA) in leukemic
blasts was related to the number of chromosomal abnorm-
alities raised the possibility that over-expression of NuMA
perturbs cell cycle progression by inhibiting mitosis result-
ing in the chromosomal instability. The finding that the
forced expression of NuMA resulted in G2/M arrest and
apoptosis clearly shows that some other genetic events,
besides aberrant expression of NuMA, are required for
malignant transformation to leukemic cells.
Characterization of the CSCs opens a new avenue for
designing novel therapeutic strategies against cancer.
However, crucial to this task will be identification of
specific cell surface antigens (markers) (Table 2) for
CSCs detection and isolation from the heterogeneous
tumor population. Hereby, membrane proteomics plays
an important role, as demonstrated by He et al. [91],
who employed the combination of lectin microarray and
liquid chromatography-tandem mass spectrometry (LC-
MS/MS) to discover novel cell surface glycoprotein mar-
kers of a glioblastoma-derived stem-like cell line. These
authors identified six differentially expressed proteins
between the stem-like glioblastoma neurosphere culture
and traditional adherent glioblastoma cell line, whereby
receptor-type tyrosine-protein phosphatase zeta, Tenas-
cin-C, Chondroitin sulfate proteoglycan NG2, Podoca-
lyxin-like protein 1 and CD90 were up-regulated, and
CD44 was down-regulated [91]. Further elucidation of
the biological roles of these proteins might prove impor-
tant for an early diagnosis and improved treatment of
glioblastoma.
Although yielding many useful information on cancer
invasiveness and progression, conventional genomic and
proteomic platforms are still limited in their capacity to
identify changes in protein activity caused by post-trans-
lational mechanisms [92]. Most proteomic techniques
Table 2 Representative cell surface markers for human
cancer stem cells
Type of cancer stem cells Cell surface markers
Acute myelogenous leukemia; CD34+, CD38-, CD44, CD123+
Chronic myeloid leukemia CD34+, CD38-, CD123+
B-acute lymphogenous
leukemia
CD34+, CD38-, CD19+
Ph1-acute lymphogenous
leukemia
CD34+, CD38-
Blast-crisis CML CD34+, CD38+, CD123+
Myeloproliferative disorder CD117+
Glioblastoma CD133+
Medulloblastoma CD133+
Pilocytic astrocytoma CD133+
Anaplastic ependymoma CD133+
Breast CD44+, CD24
-/low, ESA+
Prostate CD133+/alpha 2 beta 1 integrin/CD44+
CD44+/CD24-
Ovarian cancer CD44+, MyD88+
Colon cancer CD133+, CD44+, CD166+, E-CAMhig
Pancreatic cancer CD133+, CD44+, CD24+
Hepatocellular cancer CD133+
Head and neck squamous cell
carcinoma
CD44+
Bone sarcomas Stro-1+, CD105+, CD44+
Melanoma CD20+, CD133+
Lung cancer CD133+
Liver CD133+, CD90+
Central nervous system CD133+
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not necessarily correlate with enzyme activity, since
most enzymes are expressed as inactive zymogens or
reside in complex with their endogenous inhibitors [93].
As an alternative, a new strategy termed activity-based
protein profiling (ABPP) has emerged based on the use
of enzyme family-specific activity-based chemical probes
(ABPs) linked to specific reporter groups that by nature
only target and subsequently tag the active form of
these enzymes both in vitro and in vivo [94]. Jessani
et al. [95] used this approach to profile serine hydrolase
activities across a panel of human breast and melanoma
cancer cell lines, and found that highly invasive cancer
cells exerted secreted/membrane serine hydrolase activ-
ity profiles nearly orthogonal to those displayed by their
less aggressive counterparts indicating that invasive
cancers may share proteomic signatures that are more
reflective of their cellular phenotype than tissue of ori-
gin. Importantly, they detected the up-regulation of two
enzyme activities in invasive cancer lines, namely uroki-
nase, a secreted serine protease with previously estab-
lished role in tumor progression, and a membrane-
associated serine hydrolase KIAA1363, the latter impli-
cated as a new marker of tumor progression [95]. Simi-
lar study combining ABPP and metabolomics (rapid,
high-throughput characterization of the small molecule
metabolites including any metabolic intermediates, hor-
mones and other components of signaling pathways
found in an organism [96]) established a central role of
KIAA1363 in an ether lipid signaling network bridging
platelet-activating factor and lysophosphatidic acid [97].
As evident from these studies, integration of several dif-
ferent global profiling technologies may illuminate bio-
chemical networks pertinent to cancer development and
progression. In this respect, metabolomic profiling has
already proved beneficial in characterizing the metabolic
features of hepatocellular carcinoma [98], breast cancer
[99], renal cell carcinoma [100] and prostate cancer [101]
metastases. Metabolic alterations during cancer progression
and metastasis revealed by these studies might provide new
putative diagnostic and prognostic biomarkers as well as
new therapeutic targets, such as e.g. sarcosine, an N-methyl
derivative of glycine elevated most robustly in metastatic
prostate cancer and detectable in the urine of men with
organ-confined disease [101]. However, metabolic profiling
studies involving CSCs to identify the key metabolites
inherent to tumor progression are still scarce. The pioneer-
ing work in this field was performed at the American com-
pany Stemina Biomarker Discovery, whose scientists are
focused on identifying metabolomic biomarkers that are
potential indicators of drug efficacy against CSCs for the
establishment of novel drug screening assays (http://www.
stemina.com/web/publications.php). Specifically, they
found small molecules unique to CSCs derived from
glioblastoma multiforme (GBM), and identified unique
metabolomic footprint of three different brain tumor stem
cell lines (BTSC). Besides their potential as a screening tool
for measuring GBM presence and progression, identified
metabolite molecules might also serve as therapeutic targets
in order to manufacture drugs specifically targeting GBM
and BTSC cells.
Conclusion
Many hypotheses have been postulated to explain the
intricate nature of the metastatic process, but none of
them completely accounted for the actual biological and
clinical observations. Consequently, metastasis still
remains an open issue with only few metastasis-inducing
proteins experimentally validated so far. Global scale
proteomics studies undoubtedly revealed specific meta-
static markers often related to cell-signalling processes;
however, they proved to be patient-specific rather than
type- or tumor stage-specific, which necessitates a need
for individual therapeutic approach towards each
patient.
Due to inconsistency between experimental results and
clinical observations, a novel metastatic paradigm where
serial and parallel metastatic processes are adequately
integrated is needed to account for these differences. In
addition, organ-tropic gene signatures were shown to
bear a potential to improve patient risk stratification and
therapeutic treatment. New diagnostic tools are therefore
urgently required in clinical practice to detect patients
who will benefit from the adjuvant chemotherapy after
primary tumour resection. Consequently, this will lead to
the improvements in patient treatment and reduction of
adverse effects in patients who are traditionally unneces-
sarily treated with chemotherapy. While study of the
metastases molecular mechanisms is far from trivial, the
results discussed in this paper suggest that the benefits to
our understanding of the cellular basis of metastasis
more than justify the efforts employed.
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